Actavis Inc (ACT) 296.14 $ACT
6 Health Care Stocks John Paulson Is Betting On for 2015
at The Street - Wed Mar 04, 9:02AM CST
Here's a closer look at five health care stocks Paulson & Co. bought in the most recently reported quarter.
MNK: 116.19 (+1.34), AGN: 235.68 (+0.82), ACT: 296.14 (-0.09), VNDA: 11.06 (+0.17), SLXP: 157.13 (+0.63), MYL: 55.60 (+0.16)
Wall Street Breakfast: The Interest Rate Cuts Continue
Wall Street Breakfast - at Seeking Alpha - Wed Mar 04, 5:32AM CST
BCS: 16.03 (+0.37), ACT: 296.14 (-0.09), SNE: 27.89 (+0.06), TM: 135.52 (+0.12), RBS: 11.37 (unch), AGN: 235.68 (+0.82), SPY: 210.23 (-0.89), QQQ: 108.45 (-0.42), JPM: 62.13 (+0.16), TGT: 77.72 (-0.28), DD: 78.12 (+0.05), MSFT: 43.06 (-0.22), SWHC: 14.34 (+1.29)
Actavis sells second-largest corporate offering ever
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 1:25AM CST
AGN: 235.68 (+0.82), ACT: 296.14 (-0.09)
Actavis' Xydalba Granted Marketing Authorisation in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 1:30PM CST
Positive news flowed in for Actavis plc (ACT) when the EC granted marketing authorization to Xydalba for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
MNK: 116.19 (+1.34), IPXL: 40.40 (+0.47), LCI: 62.28 (+0.01), ACT: 296.14 (-0.09)
Jim Cramer: I'm Making My Peace With This Happy Market
at The Street - Tue Mar 03, 11:53AM CST
It's almost comical how welcoming it is these days.
VRX: 203.15 (+0.54), ACT: 296.14 (-0.09), PCYC: 230.48 (+13.72), HON: 103.05 (-0.99), UTX: 121.04 (-0.66), CAH: 89.03 (+0.60), LL: 35.64 (-5.14), AGN: 235.68 (+0.82), JNJ: 101.65 (-0.69), V: 273.75 (-1.55), IBM: 159.42 (-1.61), DPZ: 103.28 (+0.45), COST: 147.17 (-0.20), MA: 91.71 (+0.74), CODE: 37.29 (+0.17), CY: 15.20 (+0.04), HAR: 138.89 (-3.54), HD: 114.76 (-1.31), AXP: 80.63 (-1.28), SLXP: 157.13 (+0.63), DIS: 105.57 (-0.78), NXPI: 99.47 (+0.74), BA: 154.35 (-1.22), PLKI: 60.86 (-0.50), NFLX: 469.77 (-4.94), QRVO: 72.02 (+1.18), FSL: 40.36 (-0.14), AVGO: 129.40 (+1.18)
Allergan Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Tue Mar 03, 11:48AM CST
ACT: 296.14 (-0.09), BDX: 148.36 (+2.10), WFC: 54.82 (-0.63), TM: 135.52 (+0.12), AGN: 235.68 (+0.82), GS: 189.67 (-1.60), JPM: 62.13 (+0.16), FISV: 77.98 (-0.52), IBM: 159.42 (-1.61), BAX: 69.25 (-0.17), RY: 62.01 (+0.17), BPL: 76.70 (+0.17), DD: 78.12 (+0.05), TWC: 157.49 (+0.75), BRK.B: 144.92 (-1.01), INTU: 97.45 (-0.55), AAPL: 128.54 (-0.82), BRK.A: 217,612.00 (-1,388.00)
Actavis to issue senior notes in public offering in connection with pending acquisition of Allergan
M2 - Tue Mar 03, 5:00AM CST
Pharmaceutical company Actavis (NYSE:ACT) reported on Monday the launch of an offering of senior unsecured notes in multiple tranches in a registered public offering .
AGN: 235.68 (+0.82), ACT: 296.14 (-0.09)
Actavis Plc Set For Second-Largest Corporate Bond Sale Ever
Learn Bonds - at Seeking Alpha - Mon Mar 02, 11:55PM CST
Dublin based Actavis plc (NYSE: ACT ) is all set to embark on the second largest corporate bond sale ever. The pharmaceutical company will likely sell close to $20 billion in bonds as early as this week. Mike Cherney first broke the news of the deal...
RAI: 74.74 (-0.68), ACT: 296.14 (-0.09), HAL: 43.07 (-0.04)
Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan
PR Newswire - Mon Mar 02, 4:00PM CST
Actavis plc (NYSE: ACT) today announced that it has closed its concurrent offerings of 14,513,889 Ordinary Shares at $288.00 per share and 5,060,000 5.500% Mandatory Convertible Preferred Shares, Series A, at $1,000.00 per share, each having been offered in a separate registered public offering. The amounts sold include 1,319,444 Ordinary Shares and 460,000 Mandatory Convertible Preferred Shares issued pursuant to the exercise in full of the over-allotment option granted to the underwriters in each of the respective offerings to purchase additional Ordinary Shares and Mandatory Convertible Preferred Shares, respectively.
AGN: 235.68 (+0.82), ACT: 296.14 (-0.09)
Vivus - Flat Qsymia Scripts Point To Needed Shift
Spencer Osborne - at Seeking Alpha - Mon Mar 02, 10:25AM CST
OREX: 8.49 (+0.85), ACT: 296.14 (-0.09), NVO: 47.05 (-0.17), VVUS: 2.98 (+0.19), ARNA: 4.32 (+0.28)
Actavis IV antibiotic cleared in Europe
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 8:47AM CST
ACT: 296.14 (-0.09)
Actavis Receives Approval from the European Commission for XYDALBA(TM) (dalbavancin)
PR Newswire - Mon Mar 02, 7:30AM CST
DUBLIN, March 2, 2015 /PRNewswire/-- Actavis plc (NYSE: ACT) today announced that the European Commission has granted Actavis' subsidiary Durata Therapeutics International B.V., marketing authorization for XYDALBA(TM) (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. XYDALBA is the first and only once-weekly IV antibiotic approved for the treatment of ABSSSI with a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes.
DRTX: 24.16 (+0.41), ACT: 296.14 (-0.09)
Actavis Announces Proposed Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan
PR Newswire - Mon Mar 02, 6:57AM CST
Actavis plc (NYSE: ACT) today announced that it is commencing an offering of senior unsecured notes in multiple tranches in a registered public offering to be issued by its indirect subsidiary, Actavis Funding SCS, and guaranteed by certain of its other subsidiaries, subject to market and other conditions (the "Notes"
.
AGN: 235.68 (+0.82), ACT: 296.14 (-0.09)
Apple And Allergan Top Hedge Fund Holdings In Q4 2014
ValueWalk - at Seeking Alpha - Mon Mar 02, 4:28AM CST
By Clayton Browne The top 50 hedge funds continued to increase their equity exposure in the fourth quarter of 2014. Research firm FactSet published a report focusing on fourth-quarter hedge fund ownership data on Thursday, February 26th....
ZTS: 46.23 (-0.31), AGN: 235.68 (+0.82), ACT: 296.14 (-0.09), SHPG: 239.64 (+0.74), AAPL: 128.54 (-0.82)
The Best Scoring Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Sun Mar 01, 3:33AM CST
ELLI: 51.99 (-0.56), JCOM: 68.58 (+0.23), CAH: 89.03 (+0.60), CIEN: 20.60 (-0.15), AET: 101.75 (+1.96), HSP: 87.95 (+0.24), ANAC: 45.66 (+1.37), CSL: 93.22 (-0.65), CAVM: 70.83 (-0.04), HAS: 62.43 (-0.29), BCR: 167.66 (+0.48), MCHP: 51.48 (+0.05), COLM: 56.64 (+0.25), DEPO: 23.64 (+0.65), IT: 81.18 (-1.00), HRL: 57.95 (-0.42), CSX: 34.24 (+0.12), DYAX: 15.67 (+0.52), LVLT: 54.70 (-0.20), CBRL: 149.57 (-2.19), IRWD: 15.55 (-0.03), AZO: 652.48 (+0.58), EQIX: 223.83 (+2.71), KNX: 32.44 (-0.10), HAE: 44.20 (+0.18), FSL: 40.36 (-0.14), ACT: 296.14 (-0.09), BDX: 148.36 (+2.10), CCK: 52.32 (-0.69), BLL: 71.30 (-1.00), M: 62.89 (-0.58), CDW: 38.03 (-0.15), ADBE: 77.63 (-1.36), AFFX: 11.83 (+0.09), AGN: 235.68 (+0.82), DPS: 78.02 (-0.97), ANTM: 146.55 (+0.56), APH: 58.24 (+0.92), LII: 107.27 (+0.19), CNMD: 51.01 (-0.13), BJRI: 52.38 (+0.02), HBI: 32.32 (-95.63), DLX: 66.44 (-0.82), ABT: 47.01 (-0.08), ENDP: 85.65 (-0.23), DIOD: 28.36 (+0.22), LEG: 45.37 (-0.38), DIS: 105.57 (-0.78), GLW: 24.75 (+0.15), MAR: 83.15 (-0.76), LEA: 109.30 (-1.47), DISH: 75.60 (-0.25), IMAX: 34.62 (-0.17), IGV: 96.36 (-1.10), CTAS: 83.77 (-0.44), FLT: 152.11 (-2.66), FLO: 21.56 (-0.18), BIG: 47.41 (-0.28), CRM: 64.88 (-2.07)
Actavis contraceptive OK'd
at Investor's Business Daily - Fri Feb 27, 5:50PM CST
The Ireland-based drugmaker and marketing partner Medicines360 won FDA approval for a hormonal contraceptive device for women. The intrauterine device, called Liletta, releases a hormone to inhibit thickening of the womb lining, which prevents...
ACT: 296.14 (-0.09)
Meet IBD's 4 A Stocks With Rising Earnings Estimates
at Investor's Business Daily - Fri Feb 27, 3:27PM CST
Investors should look from A to Z to find the very best stocks. But right now, you can find several A-grade companies near the start of the list. IBD's Rising Estimates Screen of the Day looks for top-rated stocks on which analysts have been raising...
AGN: 235.68 (+0.82), AMBA: 67.49 (+4.44), GPRO: 43.01 (+2.71), VRX: 203.15 (+0.54), ACT: 296.14 (-0.09), UBNT: 31.72 (+0.01), SWKS: 90.15 (+1.41), AKRX: 51.19 (+1.86), AAPL: 128.54 (-0.82), AVGO: 129.40 (+1.18)
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.95 (-0.02), VRX: 203.15 (+0.54), ACT: 296.14 (-0.09), PCYC: 230.48 (+13.72), MDT: 78.19 (+0.16), CAH: 89.03 (+0.60), CLDX: 29.30 (+2.93), HSP: 87.95 (+0.24), AGN: 235.68 (+0.82), JNJ: 101.65 (-0.69), ATOS: 2.03 (+0.07), ONVO: 5.87 (+0.07), PTCT: 70.45 (+1.37), SNY: 48.34 (+0.26), PTLA: 42.88 (+1.68), INCY: 87.91 (-0.04), PFE: 34.64 (+0.08), CPHR: 11.78 (-0.22), MYL: 55.60 (+0.16), AMGN: 159.19 (+0.63), LLY: 70.65 (+0.28), BMY: 65.67 (+3.75), MNKD: 5.94 (-0.22), NKTR: 13.39 (+0.45), OMER: 26.20 (+1.20), DVA: 76.75 (+0.86), GILD: 103.06 (+0.27), SGEN: 35.12 (-0.03), ACHN: 11.63 (-0.51), MRK: 57.88 (-0.46), TEVA: 56.56 (+0.10), BIL: 45.73 (unch), ARIA: 8.10 (+0.15), NVS: 99.04 (-0.02)
Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 26, 10:50AM CST
Actavis' (ACT) infectious disease product, Avycaz, gets FDA approval.
AGN: 235.68 (+0.82), ACT: 296.14 (-0.09), BMRN: 109.79 (+1.43), CBM: 33.97 (+0.02)
6 Health Care Stocks John Paulson Is Betting On for 2015
at The Street - Wed Mar 04, 9:02AM CST
Here's a closer look at five health care stocks Paulson & Co. bought in the most recently reported quarter.
MNK: 116.19 (+1.34), AGN: 235.68 (+0.82), ACT: 296.14 (-0.09), VNDA: 11.06 (+0.17), SLXP: 157.13 (+0.63), MYL: 55.60 (+0.16)
Wall Street Breakfast: The Interest Rate Cuts Continue
Wall Street Breakfast - at Seeking Alpha - Wed Mar 04, 5:32AM CST
BCS: 16.03 (+0.37), ACT: 296.14 (-0.09), SNE: 27.89 (+0.06), TM: 135.52 (+0.12), RBS: 11.37 (unch), AGN: 235.68 (+0.82), SPY: 210.23 (-0.89), QQQ: 108.45 (-0.42), JPM: 62.13 (+0.16), TGT: 77.72 (-0.28), DD: 78.12 (+0.05), MSFT: 43.06 (-0.22), SWHC: 14.34 (+1.29)
Actavis sells second-largest corporate offering ever
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 1:25AM CST
AGN: 235.68 (+0.82), ACT: 296.14 (-0.09)
Actavis' Xydalba Granted Marketing Authorisation in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 1:30PM CST
Positive news flowed in for Actavis plc (ACT) when the EC granted marketing authorization to Xydalba for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
MNK: 116.19 (+1.34), IPXL: 40.40 (+0.47), LCI: 62.28 (+0.01), ACT: 296.14 (-0.09)
Jim Cramer: I'm Making My Peace With This Happy Market
at The Street - Tue Mar 03, 11:53AM CST
It's almost comical how welcoming it is these days.
VRX: 203.15 (+0.54), ACT: 296.14 (-0.09), PCYC: 230.48 (+13.72), HON: 103.05 (-0.99), UTX: 121.04 (-0.66), CAH: 89.03 (+0.60), LL: 35.64 (-5.14), AGN: 235.68 (+0.82), JNJ: 101.65 (-0.69), V: 273.75 (-1.55), IBM: 159.42 (-1.61), DPZ: 103.28 (+0.45), COST: 147.17 (-0.20), MA: 91.71 (+0.74), CODE: 37.29 (+0.17), CY: 15.20 (+0.04), HAR: 138.89 (-3.54), HD: 114.76 (-1.31), AXP: 80.63 (-1.28), SLXP: 157.13 (+0.63), DIS: 105.57 (-0.78), NXPI: 99.47 (+0.74), BA: 154.35 (-1.22), PLKI: 60.86 (-0.50), NFLX: 469.77 (-4.94), QRVO: 72.02 (+1.18), FSL: 40.36 (-0.14), AVGO: 129.40 (+1.18)
Allergan Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Tue Mar 03, 11:48AM CST
ACT: 296.14 (-0.09), BDX: 148.36 (+2.10), WFC: 54.82 (-0.63), TM: 135.52 (+0.12), AGN: 235.68 (+0.82), GS: 189.67 (-1.60), JPM: 62.13 (+0.16), FISV: 77.98 (-0.52), IBM: 159.42 (-1.61), BAX: 69.25 (-0.17), RY: 62.01 (+0.17), BPL: 76.70 (+0.17), DD: 78.12 (+0.05), TWC: 157.49 (+0.75), BRK.B: 144.92 (-1.01), INTU: 97.45 (-0.55), AAPL: 128.54 (-0.82), BRK.A: 217,612.00 (-1,388.00)
Actavis to issue senior notes in public offering in connection with pending acquisition of Allergan
M2 - Tue Mar 03, 5:00AM CST
Pharmaceutical company Actavis (NYSE:ACT) reported on Monday the launch of an offering of senior unsecured notes in multiple tranches in a registered public offering .
AGN: 235.68 (+0.82), ACT: 296.14 (-0.09)
Actavis Plc Set For Second-Largest Corporate Bond Sale Ever
Learn Bonds - at Seeking Alpha - Mon Mar 02, 11:55PM CST
Dublin based Actavis plc (NYSE: ACT ) is all set to embark on the second largest corporate bond sale ever. The pharmaceutical company will likely sell close to $20 billion in bonds as early as this week. Mike Cherney first broke the news of the deal...
RAI: 74.74 (-0.68), ACT: 296.14 (-0.09), HAL: 43.07 (-0.04)
Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan
PR Newswire - Mon Mar 02, 4:00PM CST
Actavis plc (NYSE: ACT) today announced that it has closed its concurrent offerings of 14,513,889 Ordinary Shares at $288.00 per share and 5,060,000 5.500% Mandatory Convertible Preferred Shares, Series A, at $1,000.00 per share, each having been offered in a separate registered public offering. The amounts sold include 1,319,444 Ordinary Shares and 460,000 Mandatory Convertible Preferred Shares issued pursuant to the exercise in full of the over-allotment option granted to the underwriters in each of the respective offerings to purchase additional Ordinary Shares and Mandatory Convertible Preferred Shares, respectively.
AGN: 235.68 (+0.82), ACT: 296.14 (-0.09)
Vivus - Flat Qsymia Scripts Point To Needed Shift
Spencer Osborne - at Seeking Alpha - Mon Mar 02, 10:25AM CST
OREX: 8.49 (+0.85), ACT: 296.14 (-0.09), NVO: 47.05 (-0.17), VVUS: 2.98 (+0.19), ARNA: 4.32 (+0.28)
Actavis IV antibiotic cleared in Europe
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 8:47AM CST
ACT: 296.14 (-0.09)
Actavis Receives Approval from the European Commission for XYDALBA(TM) (dalbavancin)
PR Newswire - Mon Mar 02, 7:30AM CST
DUBLIN, March 2, 2015 /PRNewswire/-- Actavis plc (NYSE: ACT) today announced that the European Commission has granted Actavis' subsidiary Durata Therapeutics International B.V., marketing authorization for XYDALBA(TM) (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. XYDALBA is the first and only once-weekly IV antibiotic approved for the treatment of ABSSSI with a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes.
DRTX: 24.16 (+0.41), ACT: 296.14 (-0.09)
Actavis Announces Proposed Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan
PR Newswire - Mon Mar 02, 6:57AM CST
Actavis plc (NYSE: ACT) today announced that it is commencing an offering of senior unsecured notes in multiple tranches in a registered public offering to be issued by its indirect subsidiary, Actavis Funding SCS, and guaranteed by certain of its other subsidiaries, subject to market and other conditions (the "Notes"
. AGN: 235.68 (+0.82), ACT: 296.14 (-0.09)
Apple And Allergan Top Hedge Fund Holdings In Q4 2014
ValueWalk - at Seeking Alpha - Mon Mar 02, 4:28AM CST
By Clayton Browne The top 50 hedge funds continued to increase their equity exposure in the fourth quarter of 2014. Research firm FactSet published a report focusing on fourth-quarter hedge fund ownership data on Thursday, February 26th....
ZTS: 46.23 (-0.31), AGN: 235.68 (+0.82), ACT: 296.14 (-0.09), SHPG: 239.64 (+0.74), AAPL: 128.54 (-0.82)
The Best Scoring Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Sun Mar 01, 3:33AM CST
ELLI: 51.99 (-0.56), JCOM: 68.58 (+0.23), CAH: 89.03 (+0.60), CIEN: 20.60 (-0.15), AET: 101.75 (+1.96), HSP: 87.95 (+0.24), ANAC: 45.66 (+1.37), CSL: 93.22 (-0.65), CAVM: 70.83 (-0.04), HAS: 62.43 (-0.29), BCR: 167.66 (+0.48), MCHP: 51.48 (+0.05), COLM: 56.64 (+0.25), DEPO: 23.64 (+0.65), IT: 81.18 (-1.00), HRL: 57.95 (-0.42), CSX: 34.24 (+0.12), DYAX: 15.67 (+0.52), LVLT: 54.70 (-0.20), CBRL: 149.57 (-2.19), IRWD: 15.55 (-0.03), AZO: 652.48 (+0.58), EQIX: 223.83 (+2.71), KNX: 32.44 (-0.10), HAE: 44.20 (+0.18), FSL: 40.36 (-0.14), ACT: 296.14 (-0.09), BDX: 148.36 (+2.10), CCK: 52.32 (-0.69), BLL: 71.30 (-1.00), M: 62.89 (-0.58), CDW: 38.03 (-0.15), ADBE: 77.63 (-1.36), AFFX: 11.83 (+0.09), AGN: 235.68 (+0.82), DPS: 78.02 (-0.97), ANTM: 146.55 (+0.56), APH: 58.24 (+0.92), LII: 107.27 (+0.19), CNMD: 51.01 (-0.13), BJRI: 52.38 (+0.02), HBI: 32.32 (-95.63), DLX: 66.44 (-0.82), ABT: 47.01 (-0.08), ENDP: 85.65 (-0.23), DIOD: 28.36 (+0.22), LEG: 45.37 (-0.38), DIS: 105.57 (-0.78), GLW: 24.75 (+0.15), MAR: 83.15 (-0.76), LEA: 109.30 (-1.47), DISH: 75.60 (-0.25), IMAX: 34.62 (-0.17), IGV: 96.36 (-1.10), CTAS: 83.77 (-0.44), FLT: 152.11 (-2.66), FLO: 21.56 (-0.18), BIG: 47.41 (-0.28), CRM: 64.88 (-2.07)
Actavis contraceptive OK'd
at Investor's Business Daily - Fri Feb 27, 5:50PM CST
The Ireland-based drugmaker and marketing partner Medicines360 won FDA approval for a hormonal contraceptive device for women. The intrauterine device, called Liletta, releases a hormone to inhibit thickening of the womb lining, which prevents...
ACT: 296.14 (-0.09)
Meet IBD's 4 A Stocks With Rising Earnings Estimates
at Investor's Business Daily - Fri Feb 27, 3:27PM CST
Investors should look from A to Z to find the very best stocks. But right now, you can find several A-grade companies near the start of the list. IBD's Rising Estimates Screen of the Day looks for top-rated stocks on which analysts have been raising...
AGN: 235.68 (+0.82), AMBA: 67.49 (+4.44), GPRO: 43.01 (+2.71), VRX: 203.15 (+0.54), ACT: 296.14 (-0.09), UBNT: 31.72 (+0.01), SWKS: 90.15 (+1.41), AKRX: 51.19 (+1.86), AAPL: 128.54 (-0.82), AVGO: 129.40 (+1.18)
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.95 (-0.02), VRX: 203.15 (+0.54), ACT: 296.14 (-0.09), PCYC: 230.48 (+13.72), MDT: 78.19 (+0.16), CAH: 89.03 (+0.60), CLDX: 29.30 (+2.93), HSP: 87.95 (+0.24), AGN: 235.68 (+0.82), JNJ: 101.65 (-0.69), ATOS: 2.03 (+0.07), ONVO: 5.87 (+0.07), PTCT: 70.45 (+1.37), SNY: 48.34 (+0.26), PTLA: 42.88 (+1.68), INCY: 87.91 (-0.04), PFE: 34.64 (+0.08), CPHR: 11.78 (-0.22), MYL: 55.60 (+0.16), AMGN: 159.19 (+0.63), LLY: 70.65 (+0.28), BMY: 65.67 (+3.75), MNKD: 5.94 (-0.22), NKTR: 13.39 (+0.45), OMER: 26.20 (+1.20), DVA: 76.75 (+0.86), GILD: 103.06 (+0.27), SGEN: 35.12 (-0.03), ACHN: 11.63 (-0.51), MRK: 57.88 (-0.46), TEVA: 56.56 (+0.10), BIL: 45.73 (unch), ARIA: 8.10 (+0.15), NVS: 99.04 (-0.02)
Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 26, 10:50AM CST
Actavis' (ACT) infectious disease product, Avycaz, gets FDA approval.
AGN: 235.68 (+0.82), ACT: 296.14 (-0.09), BMRN: 109.79 (+1.43), CBM: 33.97 (+0.02)
